NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…